Ascentage Pharma's issued share capital rises in August

Ascentage Pharma Group International's latest monthly return reveals an increase in its issued share capital, with the total number of issued ordinary shares rising to 372,671,212 by the end of August 2025, up from 371,853,475 at the close of the preceding month. This represents an increase of 817,737 shares. The company’s authorized/registered share capital remained stable at 500,000,000 ordinary shares, with a par value of $0.0001, totaling $50,000.

The increase in issued shares was primarily driven by the exercise of share options and other agreements. Specifically, 815 new ordinary shares were issued under the Pre-IPO Share Option Scheme, raising HK$8.15. Additionally, 816,922 ordinary shares were issued through other agreements or arrangements, which include various RSU Schemes.

As of August 31, 2025, 2,154,197 share options remain outstanding under the Pre-IPO Share Option Scheme, with 966,880 shares potentially issuable upon their exercise. The company also confirmed adherence to all listing rules and regulatory requirements concerning these movements.